InSilicoTrials Technologies
We are Hyper-accelerate drug and medical device development. Computational models and AI allow to dramatically accelerate the development of new drugs and medical devices, to reduce, refine and replace tests on animals and clinical trials, to improve the safety of medical products and significantly cut R&D costs.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
Welcome
Modeling & Simulation combined with artificial intelligence is the most effective way to innovate the R&D process in healthcare. Already successfully used for decades in many industrial sectors, this cutting-edge technology is finally about to revolutionize the medical industry. A computational approach can increase the safety of drugs and medical devices, while significantly reducing their development cost and the time to market.
- Accelerate the development of new drugs and medical devices
- Significantly cut R&D costs
- Improve the safety of medical products
- Reduce, refine and replace tests on animals and clinical trials
We have built a unique cloud platform where powerful computational models, developed by top scientists at renowned universities, research centers and companies worldwide, are made available to the healthcare industry in an easy-to-use and cost-effective manner. Our game-changing approach to Modeling & Simulation means faster and way less expensive R&D for safer drugs and medical devices.
Our technology
We provide a series of cloud-based digital solutions that integrate computational models, so our clients do not need to worry about developing their own solutions and paying for very expensive software, IT infrastructures, and specialized personnel. The cloud guarantees total data security and the possibility to access the platform from everywhere in the world.
About Us
We are a team of passionate life sciences, cybersecurity and digital innovation experts.
OUR MISSION:
Hyper-accelerate drug and medical device development through in silico trials executed on our platform.
OUR VISION:
Boost the world’s transition to accessible therapies.
As one of our main objectives is to hyper-accelerate innovation in the Pharma and MedTech industry, we are addressing several sustainable development goals (SDGs).
In particular, we are actively involved with the third SDG – Good Health and Well-being (Ensure healthy lives and promote well-being for all at all ages) with a specific focus on target 3.B – support research, development, and universal access to affordable vaccines and medicines. Our technology allows for significant cost and time savings in drug development, which results in faster-to- market medicines and medical devices.
Another goal we actively tackle is SDG 9 – Industry, Innovation, and Infrastructure (Build resilient infrastructure, promote inclusive and sustainable industrialization, and foster innovation) with a specific focus on target 9.5 – enhance research and upgrade industrial technologies.
With our platform, we want to make in silico trials more accessible to all Pharma and medical devices companies – even to SMEs and emerging BioTechs that usually don’t have the same competitive budget as established Big Pharma to perform clinical trials.
We are also committed to a long-term goal: the reduction and replacement of animals in research since in silico trials can be used as substitutes for in vivo testing.
InSilicoTrials is an Equal Opportunity Employer. All our employees have been and will be selected without regard to race, color, age, religion, sex, sexual orientation, gender identity /expression and national origin. As a company with 16 employees representing 6 different nationalities, InSilicoTrials is committed to foster and deliver innovation through a diverse workforce and a fast-paced inclusive environment.
Gender diversity is central to our inclusion policies. In fact, gender representation criteria are integrated into our hiring metrics allowing 50% of female employees within our team with equal and competitive remuneration plans.